Sales & Marketing

The faces and names behind the year's best pharmaceutical advertising.

IMS Health reports a nice increase in prescription sales from 2008 to 2009, even with a recession in full swing. That said, numbers are still well below the historic sales of a few years back, and it's anyone's guess if they will reach that high again.

The number of consumers ditching their drugs at the pharmacy keeps climbing as the economy worsens.

Three ad agencies came up with two similarly designed ways of keeping track of online healthcare conversation, harnessing the power of social media sites like Twitter and Digg.

The faces and names behind the year's best pharmaceutical advertising.

The faces and names behind the year's best pharmaceutical advertising.

The faces and names behind the year's best pharmaceutical advertising.

The faces and names behind the year's best pharmaceutical advertising.

The faces and names behind the year's best pharmaceutical advertising.

The faces and names behind the year's best pharmaceutical advertising.

The faces and names behind the year's best pharmaceutical advertising.

The faces and names behind the year's best pharmaceutical advertising.

The faces and names behind the year's best pharmaceutical advertising.

The faces and names behind the year's best pharmaceutical advertising.

The faces and names behind the year's best pharmaceutical advertising.

The faces and names behind the year's best pharmaceutical advertising.

Pfizer's strategy to use Wyeth's drug pipeline to increase its sales has paid off as the drug giant announced that its fourth quarter earnings nearly doubled year-to-year. Too bad investors are running in fear of an ugly 2010 forecast.

Improving field force business planning requires managers to run each sales territory as if it is a self-contained business operation.

Sales compensation practices are due for an overhaul in 2010.

All eyes are on PatientsLikeMe's new epilepsy site. The social network is backed by UCB, but the pharma firm is taking a hands-off approach. Is this the future of pharma social media?

AIDS treatment provider says the high price of Merck's Isentress is limiting patient access. Merck says banning its reps is what limits access. While Mom and Dad are fighting, does the patient lose out?

Pharm Exec's 2010 crystal ball reveals an industry in upheaval on many fronts. Is going back to the future the answer?

A new JAMA study reveals that antidepressants might not have as strong an effect on people with less severe cases of depression. How this will affect the pharma industry, which once made heaps of cash with drugs like Prozac, remains to be seen.

In a new era of research partnerships, targeted information databases can improve collaborative decision making and speed new medicines to market.

New tools are beig applied to make patient advocacy powerful and measurable.

The rules of the game have changed. While pharmaceutical executives have been busy trying to keep up with a radically shifting marketing landscape, technology has swept in and changed everything marketers held sacred.

With the fourth quarter quickly coming to a close, talks of job cuts are once again in the air. The first major layoffs could be coming at Sanofi-Aventis, which is rumored to be slashing up to 1,500 positions.

Marketers will need to address not only the benefits of the therapy but also the benefits of a diagnostic assay.

Process-driven managed-care rebating programs can drive profitability

Feds targeted 136 Web sites offering foreign or unapproved drugs as part of International Internet Week of Action. But does the FDA campaign ignore a larger crisis endangering consumers?